Ligand Pharmaceuticals Inc
LGDN
Company Profile
Business description
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Contact
555 Heritage Drive
Suite 200
JupiterFL33458
USAT: +1 858 550-7500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
68
Stocks News & Analysis
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,918.30 | 4.70 | 0.05% |
| CAC 40 | 8,151.38 | 0.74 | 0.01% |
| DAX 40 | 24,288.40 | 88.90 | 0.37% |
| Dow JONES (US) | 48,134.89 | 183.04 | 0.38% |
| FTSE 100 | 9,897.42 | 59.65 | 0.61% |
| HKSE | 25,690.53 | 192.40 | 0.75% |
| NASDAQ | 23,307.62 | 301.26 | 1.31% |
| Nikkei 225 | 49,507.21 | 505.71 | 1.03% |
| NZX 50 Index | 13,333.40 | 76.63 | 0.58% |
| S&P 500 | 6,834.50 | 59.74 | 0.88% |
| S&P/ASX 200 | 8,621.40 | 0.10 | -0.00% |
| SSE Composite Index | 3,890.45 | 14.08 | 0.36% |